L'irradiation corporelle totale : Les indications actuelles

The choice of dose and fractionation for total body irradiation is made difficult by the large number of considerations to be taken into account. The outcome of bone marrow transplantation after total body irradiation can be understood in terms of tumour cell killing, engraftment, and normal tissue damage, each of these endpoints being influenced by irradiation-, disease-, transplant-, and patient-related factors. Interpretation of clinical data is further hampered by the overwhelming influence of logistic constraints, the small numbers of randomised studies, and the concomitant variations in total dose and fraction size or dose rate. So far, three cautious conclusions can be drawn in order to tentatively adapt the total body irradiation schedule to clinically-relevant situations. Firstly, the organs at risk for normal tissue damage (lung, liver, lens, kidney) are protected by delivering small doses per fraction at low dose rate. This suggests that, when toxicity is at stake (e.g., in children), fractionated irradiation should be preferred, provided that interfraction intervals are long enough. Secondly, fractionated irradiation should be avoided in case of T-cell depleted transplant, given the high risk of graft rejection in this setting. An alternative would be to increase total (or fractional) dose of fractionated total body irradiation, but this approach is likely to induce more normal tissue toxicity. Thirdly, clinical data have shown higher relapse rates in chronic myeloid leukaemia after fractionated or low dose rate total body irradiation, suggesting that fractionated irradiation should not be recommended, unless total (or fractional) dose is increased. Total body irradiation-containing regimens, primarily cyclophosphamide/total body irradiation, are either equivalent to or better than the chemotherapy-only regimens, primarily busulfan/cyclophosphamide. Busulfan/cyclophosphamide certainly represents a reasonable alternative, especially in patients who may not be eligible for total body irradiation because of prior irradiation to critical organs.

[1]  R. Gale,et al.  What does total body irradiation do in bone marrow transplants for leukemia? , 1991, International journal of radiation oncology, biology, physics.

[2]  B. Dubray,et al.  Radiobiological and Clinical Bases for Total Body Irradiation in the Leukemias and Lymphomas. , 1995, Seminars in radiation oncology.

[3]  C. Song,et al.  Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. , 1993, Cancer research.

[4]  B. Dubray,et al.  Fractionation Sensitivity of Mammalian Tissues , 1994 .

[5]  F. Khan,et al.  Radiobiological basis of total body irradiation with different dose rate and fractionation: repair capacity of hemopoietic cells. , 1981, International journal of radiation oncology, biology, physics.

[6]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[7]  D. Harrison Competitive repopulation in unirradiated normal recipients [editorial; comment] , 1993 .

[8]  E. Copelan,et al.  Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. , 1989, Transplantation proceedings.

[9]  W. Woods,et al.  Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. , 1995, International journal of radiation oncology, biology, physics.

[10]  J. Klijanienko,et al.  In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  D. Blaise,et al.  Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments] , 1992 .

[12]  L. Peters Discussion: The radiobiological bases of tbi , 1980 .

[13]  G. Leverger,et al.  Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Rimm,et al.  Increasing Utilization of Allogeneic Bone Marrow Transplantation , 1992, Annals of Internal Medicine.

[15]  S. A. Bush,et al.  Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. , 1995, Blood.

[16]  E. Cronkite,et al.  Radioactivity: Effects of Whole Body Irradiation , 1952 .

[17]  E. Thomas,et al.  Irradiation of the entire body and marrow transplantation: some observations and comments. , 1959, Blood.

[18]  B. Shank Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation? , 1995, International journal of radiation oncology, biology, physics.

[19]  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group , 1994 .

[20]  Pène,et al.  Morbidity After Total Body Irradiation. , 1994, Seminars in radiation oncology.

[21]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[22]  James B. Murphy HETEROPLASTIC TISSUE GRAFTING EFFECTED THROUGH ROENTGEN-RAY LYMPHOID DESTRUCTION , 1914 .

[23]  J Sullivan,et al.  Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. , 1995, International journal of radiation oncology, biology, physics.

[24]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[25]  D. Blaise,et al.  Fractionated or single-dose total body irradiation in 171 acute myeloblastic leukemias in first complete remission: is there a best choice? SFGM. Société Française de Greffe de Moelle. , 1995, International journal of radiation oncology, biology, physics.

[26]  B. Dubray,et al.  Single dose versus fractionated total body irradiation before bone marrow transplantation: radiobiological and clinical considerations. , 1994, International journal of radiation oncology, biology, physics.

[27]  J. Van Dyk,et al.  Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: effect of different dose rates and fractionation. , 1994, International journal of radiation oncology, biology, physics.

[28]  H. Vriesendorp Radiobiological speculations on therapeutic total body irradiation. , 1990, Critical reviews in oncology/hematology.

[29]  D. Blaise,et al.  Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). , 1995, Blood.